Skip to main content
SpringerLink
Log in

Lancefield Whole Blood Killing Assay to Evaluate Vaccine Efficacy

  • Protocol
  • First Online:
Group A Streptococcus

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2136))

Abstract

While the Lancefield whole blood killing assay is named after the renowned streptococcal researcher Rebecca Lancefield, the protocol was first described by Todd in 1927 (Br J Exp Pathol 8:1–5, 1927). Initially, the assay was used to identify novel Group A Streptococcal (GAS) serotypes through the supplementation of non-immune human blood (often from infants) with type-specific antisera prepared in rabbits (Lancefield, J Exp Med 106:525–544, 1957; Maxted, Br J Exp Pathol 37:415–422, 1956) and to demonstrate the impressive longevity of type-specific immunity in patients following invasive GAS infection (Lancefield, J Exp Med 110:271–292, 1959). The modern assay is routinely used to screen defined GAS mutants (Wessels, Bronze, Proc Natl Acad Sci U S A 91:12238–12242, 1994; Zinkernagel et al., Cell Host Microbe 4:170–178, 2008) or transposon libraries (Le Breton et al., Infect Immun 81:862-875, 2013) for enhanced susceptibility to opsonophagocytic killing or to screen vaccine antisera (Salehi et al., mSphere 3:e00617–e00618, 2018) or other serological preparations (Reglinski et al., Sci Rep 5:15825, 2015) for anti-streptococcal activity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Todd EW (1927) A method of measuring the increase or decrease of the population of Hæmolytic streptococci in blood. Br J Exp Pathol 8(1):1–5

    PubMed Central  Google Scholar 

  2. Lancefield RC (1957) Differentiation of group a streptococci with a common R antigen into three serological types, with special reference to the bactericidal test. J Exp Med 106(4):525–544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Maxted WR (1956) The indirect bactericidal test as a means of identifying antibody to the M antigen of Streptococcus pyogenes. Br J Exp Pathol 37(4):415–422

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Lancefield RC (1959) Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med 110(2):271–292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wessels MR, Bronze MS (1994) Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc Natl Acad Sci U S A 91(25):12238–12242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zinkernagel AS, Timmer AM, Pence MA et al (2008) The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 4(2):170–178. https://doi.org/10.1016/j.chom.2008.07.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Le Breton Y, Mistry P, Valdes KM et al (2013) Genome-wide identification of genes required for fitness of group A Streptococcus in human blood. Infect Immun 81(3):862–875. https://doi.org/10.1128/iai.00837-12

    Article  PubMed  PubMed Central  Google Scholar 

  8. Salehi S, Hohn CM, Penfound TA, Dale JB (2018) Development of an Opsonophagocytic killing assay using HL-60 cells for detection of functional antibodies against Streptococcus pyogenes. mSphere 3(6):e00617–e00618. https://doi.org/10.1128/mSphere.00617-18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Reglinski M, Gierula M, Lynskey NN et al (2015) Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin. Sci Rep 5:15825. https://doi.org/10.1038/srep15825srep15825

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rothbard S (1945) Bacteriostatic effect of human sera on group A Streptococci: II. Comparative bacteriostatic effect of Normal whole blood from different animal species in the presence of human convalescent sera. J Exp Med 82(2):107–118

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stollerman GH, Kantor FS, Gordon BD (1958) Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A Streptococci. I. A typical behavior of some human and rabbit bloods. J Exp Med 108(4):475–491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stollerman GH, Rytel M, Ortiz J (1963) Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A Streptococci. II. Human plasma cofactor (s) enhancing opsonization of encapsulated organisms. J Exp Med 117:1–17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kahlich R, Svec M, Prochazka O (1983) Complex surveillance of streptococcus pyogenes. VI. Relationship between hypersensitivity to zymosan and indicators of immunity against group A streptococci. J Hyg Epidemiol Microbiol Immunol 27(2):219–228

    CAS  PubMed  Google Scholar 

  14. Unnikrishnan M, Cohen J, Sriskandan S (2001) Complementation of a speA negative Streptococcus pyogenes with speA: effects on virulence and production of streptococcal pyrogenic exotoxin A. Microb Pathog 31(3):109–114. https://doi.org/10.1006/mpat.2001.0453

    Article  CAS  PubMed  Google Scholar 

  15. Bauer MJ, Georgousakis MM, Vu T et al (2012) Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Vaccine 30(12):2197–2205. https://doi.org/10.1016/j.vaccine.2011.12.115

    Article  CAS  PubMed  Google Scholar 

  16. Reglinski M, Lynskey NN, Sriskandan S (2016) Modification of the classical Lancefield assay of group A streptococcal killing to reduce inter-donor variation. J Microbiol Methods 124:69–71. https://doi.org/10.1016/j.mimet.2016.03.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Courtney HS, Hasty DL, Dale JB (2006) Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. Mol Microbiol 59(3):936–947. https://doi.org/10.1111/j.1365-2958.2005.04977.x

    Article  CAS  PubMed  Google Scholar 

  18. Lannergard J, Gustafsson MC, Waldemarsson J et al (2011) The Hypervariable region of Streptococcus pyogenes M protein escapes antibody attack by antigenic variation and weak immunogenicity. Cell Host Microbe 10(2):147–157. https://doi.org/10.1016/j.chom.2011.06.011

    Article  CAS  PubMed  Google Scholar 

  19. Wittner MK, Fox EN (1977) Homologous and heterologous protection of mice with group A streptococcal M protein vaccines. Infect Immun 15(1):104–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bronze MS, McKinsey DS, Beachey EH, Dale JB (1988) Protective immunity evoked by locally administered group A streptococcal vaccines in mice. J Immunol 141(8):2767–2770

    CAS  PubMed  Google Scholar 

  21. Keefer CS, Spink WW (1936) Studies of hemolytic streptococcal infection I. Factors influencing the outcome of erysipelas. J Clin Invest 15(1):17–19. https://doi.org/10.1172/JCI100754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fuller AT, Colebrook L, Maxted WR (1939) Factors which determine the fate of hæmolytic streptococci (group A) in shed blood and in serum. J Pathol Bacteriol 48(2):443–464. https://doi.org/10.1002/path.1700480217

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Microbiology, School of Life Sciences, University of Dundee, Dundee, UK

    Mark Reglinski

Authors
  1. Mark Reglinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Reglinski .

Editor information

Editors and Affiliations

  1. School of Medical Sciences, The University of Auckland, Auckland, New Zealand

    Thomas Proft

  2. School of Medical Sciences, The University of Auckland, Auckland, New Zealand

    Jacelyn M. S. Loh

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Reglinski, M. (2020). Lancefield Whole Blood Killing Assay to Evaluate Vaccine Efficacy. In: Proft, T., Loh, J. (eds) Group A Streptococcus. Methods in Molecular Biology, vol 2136. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0467-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0467-0_25

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0466-3

  • Online ISBN: 978-1-0716-0467-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation